Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

The Concept of Immunological Surveillance

2015 • 1,586 citations

Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo

1999 • 1,066 citations

Identification of human cancers deficient in antigen processing.

1993 • 625 citations

A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens

1999 • 578 citations

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1996 • 398 citations

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1999 • 366 citations

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells

1999 • 341 citations

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1998 • 246 citations

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1999 • 242 citations

Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer

1995 • 240 citations

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

1999 • 191 citations

Loss of HLA class I expression in prostate cancer: Implications for immunotherapy

1995 • 189 citations

Tumor antigens recognized by T lymphocytes

1997 • 153 citations

Follow-up evaluation of a phase II prostate cancer vaccine trial

1999 • 147 citations

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.

1998 • 111 citations

Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms

1993 • 107 citations

Response criteria for the prostate of the USA national prostatic cancer project

1980 • 97 citations

Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule.

1992 • 92 citations

Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy

1998 • 86 citations

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

1998 • 67 citations

Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon γ and lipopolysaccharide

1997 • 52 citations

Monitoring of Cancer Patients Undergoing Active or Passive Immunotherapy

1997 • 18 citations